51229-51-7

Basic information

• Product Name: 1-(4-(Bromomethyl)phenyl)ethanone
• Synonyms: 1-(4-(Bromomethyl)phenyl)ethanone;4'-BROMOMETHYLACETOPHENONE;Ethanone, 1-[4-(broMoMethyl)phenyl]-;1-[4-(broMoMethyl)phenyl]ethan-1-one;p-(Bromomethyl)acetophenone;p-Acetylbenzyl bromide;1-(4-(Bromomethyl)
• CAS NO: 51229-51-7
• Molecular Formula: C₉H₉BrO
• Molecular Weight: 213.073
• Mol File: 51229-51-7.mol

Chemical Properties

• Melting Point: 38.5-40.0℃
• Boiling Point: 134-136℃ (5 Torr)
• Flash Point: 94.1 °C
• Appearance: /
• Density: 1.416 g/cm³
• Vapor Pressure: 0.00195mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 1-(4-(Bromomethyl)phenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-(Bromomethyl)phenyl)ethanone(51229-51-7)
• EPA Substance Registry System: 1-(4-(Bromomethyl)phenyl)ethanone(51229-51-7)

Safety Data

• Hazardous Substances Data: 51229-51-7(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Synthesis:
1-(4-(Bromomethyl)phenyl)ethanone is used as an intermediate in the synthesis of various pharmaceutical compounds, particularly for the creation of dihydropyrimidine and thiopyrimidine derivatives. These derivatives have demonstrated antiviral properties, making them important in the development of new antiviral agents to combat viral infections.
2. Used in Chemical Research:
In the field of chemical research, 1-(4-(Bromomethyl)phenyl)ethanone serves as a versatile building block for the synthesis of a wide range of organic molecules. Its unique structure allows for further functionalization and modification, which can lead to the discovery of new compounds with potential applications in various industries.
3. Used in Material Science:
1-(4-(Bromomethyl)phenyl)ethanone may also find applications in material science, where its specific chemical properties could be exploited to develop new materials with tailored characteristics. For instance, its reactivity with other molecules could be utilized in the creation of novel polymers or coatings with specific properties.

InChI:InChI=1/C9H9BrO/c1-7(11)9-4-2-8(6-10)3-5-9/h2-5H,6H2,1H3

Upstream product

• 122-00-9 para-methylacetophenone 
• 75633-63-5 4-(hydroxymethyl)acetophenone 
• 622-96-8 4-methylethylbenzene 
• 78-67-1 2,2'-azobis(isobutyronitrile) 
• 108-88-3 toluene 

Downstream Products

• 71348-24-8 methyl (2E)-3-(4-acetylphenyl)acrylate 
• 51229-55-1 1-{4-[(phenylthio)methyl]phenyl}ethan-1-one 
• 124667-88-5 2'-O-acetyl-4-O-(4-acetylbenzyl)tylosin 
• 51229-60-8 (4-Acetyl-benzyl)-phenyl-sulfon 
• 75633-63-5 4-(hydroxymethyl)acetophenone 
• 10266-42-9 2-(4-acetylphenyl)acetonitrile 
• 149879-69-6 1-{4-[3-(4-acetyl-benzyloxy)-5-hydroxymethyl-phenoxymethyl]-phenyl}-ethanone 
• 223513-47-1 1-(4-(azidomethyl)phenyl)ethan-1-one 
• 878556-00-4 tert-butyl ([(4-acetylphenyl)acetyl]{2-[(9H-fluoren-9-ylmethoxycarbonyl)amino]ethyl}amino)acetate 
• 7398-52-9 4-acetyl-phenylacetic acid 
• 152595-77-2 1-[4-(3-Hydroxy-5-trifluoromethyl-1H-pyrazol-4-ylmethyl)-phenyl]-ethanone 
• 68064-47-1 4-Methyl-4'-(4-methylcinnamoyl)stilben 
• 41468-01-3 (E)-1-(4-(4-nitrostyryl)phenyl)ethanone 
• 20488-43-1 4-acetyl-trans-stilbene 

Relevant articles and documents

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

In this study, a series of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives were designed, synthesized, and evaluated for their biological activities. Upon performing kinase assays, most of the compounds exhibited potent inhibition against JAK2/3 and Aurora A/B with the IC50 values ranging from 0.008 to 2.52 μM. Among these derivatives, compound 10e expressed the most moderate inhibiting activities against all the four kinases with the IC50 values of 0.166 μM (JAK2), 0.057 μM (JAK3), 0.939 μM (Aurora A), and 0.583 μM (Aurora B), respectively. Moreover, most of the derived compounds exhibited potent cytotoxicity against human chronic myeloid leukemia cells K562 and human colon cancer cells HCT116, while compound 10e expressed antiproliferative activities against K562 (IC50=6.726 μM). According to western blot analysis, compound 10e down-regulated the phosphorylation of STAT3, STAT5, Aurora A, and Aurora B in a dose-dependent manner in K562 and HCT116 cells. Cell cycle analysis revealed that compound 10e inhibited the proliferation of cells by inducing cell cycle arrest in the G2 phase. The molecular modeling suggested that compound 10e could maintain a binding mode similar to the binding mode of AT9832, a common JAK 2/3 and Aurora A/B kinases multi-target kinase inhibitor. Therefore, compound 10e might be a potential agent for cancer therapy deserving further research.

Photocatalytic continuous bromination method

The invention provides a photocatalytic continuous bromination method. The method comprises the following steps: carrying out a first-stage photocatalytic continuous bromination reaction on a materialcontaining an aromatic substrate with a structural general formula I and a bromination reagent in a first continuous illumination reactor to form a first continuous system; overflowing the obtained first continuous system into a second continuous illumination reactor for a second-stage photocatalytic continuous bromination reaction to form a second continuous system; and purifying the second continuous system, wherein the structural general formula I is shown in the specification, R is selected from any one of carboxyl, ester group, NO2, CN, C1 to C8 alkyl and alkoxy, and R1 is C1 to C8 alkyl; n is 1 or 2; X is N or C, and the bromination reagent is Nbromo succinimide or dibromohydantoin. According to the bromination reagent, the selectivity of a product is improved, so the yield of the product is improved; the photocatalytic continuous bromination reaction of the two stages effectively relieves the reaction heat accumulation, and enhances the yield of the target product.

Non-natural amino acid and application thereof Recombinant protein and recombinant protein conjugate comprising same

The invention provides a non-natural amino acid. A compound represented by formula (I) or an enantiomer thereof. The invention also provides application of the non-natural amino acid. Further, the present invention also provides a protein conjugate comprising the recombinant protein and of the non-natural amino acid prepared from the recombinant protein. The non-natural amino acid provided by the invention is simple and convenient to prepare, good in safety, not prone to inactivation during protein insertion, high in conjugate rate with a coupling part, and higher in stability of the obtained conjugate.

Dual-Metal N-Heterocyclic Carbene Complex (M = Au and Pd)-Functionalized UiO-67 MOF for Alkyne Hydration-Suzuki Coupling Tandem Reaction

Metal N-heterocyclic carbene complexes (NHC-M) have been recognized as an important class of organometallic catalysts. Herein, we demonstrate that different NHC-M (M = Au and Pd) species can be simultaneously introduced into a single metal organic framework (MOF) by direct assembly of NHC-M-decorated ligands and metal ions under solvothermal conditions. The obtained UiO-67-Au/Pd-NHBC MOF with different organometallic NHC-M species can be a highly reusable dual catalyst to sequentially promote alkyne hydration-Suzuki coupling reaction. The potential utility of this strategy is highlighted by the preparation of many more new multicatalysts of this type for various organic transformations in a sequential way.

3-(4-phenyl-1H-2-imidazolyl)-1H-pyrazole compound as well as preparation method and application thereof

The invention relates to a 3-(4-phenyl-1H-2-imidazolyl)-1H-pyrazole compound as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry and pharmacotherapeutics. The invention provides application of a compound shown as a formula I or pharmaceutically acceptable salt thereof in preparation of drugs for treating tumor-related diseases, particularly an application in preparation of an Aurora A kinase specific inhibitor.

HYDROXYISOXAZOLINES AND DERIVATIVES THEREOF

The present disclosure relates to the use of hydroxyisoxazolines and derivatives thereof as fungicide. It also relates to new hydroxyisoxazolines derivatives, their use as fungicide and compositions comprising thereof.

Exploiting the chalcone scaffold to develop multifunctional agents for Alzheimer’s disease

Alzheimer’s disease still represents an untreated multifaceted pathology, and drugs able to stop or reverse its progression are urgently needed. In this paper, a series of naturally inspired chalcone-based derivatives were designed as structural simplification of our previously reported benzofuran lead compound, aiming at targeting both acetyl (AChE)- and butyryl (BuChE) cholinesterases that, despite having been studied for years, still deserve considerable attention. In addition, the new compounds could also modulate different pathways involved in disease progression, due to the peculiar trans-α,β-unsaturated ketone in the chalcone framework. All molecules presented in this study were evaluated for cholinesterase inhibition on the human enzymes and for antioxidant and neuroprotective activities on a SH-SY5Y cell line. The results proved that almost all the new compounds were low micromolar inhibitors, showing different selectivity depending on the appended substituent; some of them were also effective antioxidant and neuroprotective agents. In particular, compound 4, endowed with dual AChE/BuChE inhibitory activity, was able to decrease ROS formation and increase GSH levels, resulting in enhanced antioxidant endogenous defense. Moreover, this compound also proved to counteract the neurotoxicity elicited by Aβ1–42 oligomers, showing a promising neuroprotective potential.

A Selective and Functional Group-Tolerant Ruthenium-Catalyzed Olefin Metathesis/Transfer Hydrogenation Tandem Sequence Using Formic Acid as Hydrogen Source

A ruthenium-catalyzed transfer hydrogenation of olefins utilizing formic acid as a hydrogen donor is described. The application of commercially available alkylidene ruthenium complexes opens access to attractive C(sp3)-C(sp3) bond formation in an olefin metathesis/transfer hydrogenation sequence under tandem catalysis conditions. High chemoselectivity of the developed methodology provides a remarkable synthetic tool for the reduction of various functionalized alkenes under mild reaction conditions. The developed methodology is applied for the formal synthesis of the drugs pentoxyverine and bencyclane.

Carbonylative Coupling of Alkyl Zinc Reagents with Benzyl Bromides Catalyzed by a Nickel/NN2 Pincer Ligand Complex

An efficient catalytic protocol for the three-component assembly of benzyl bromides, carbon monoxide, and alkyl zinc reagents to give benzyl alkyl ketones is described, and represents the first nickel-catalyzed carbonylative coupling of two sp3-carbon fragments. The method, which relies on the application of nickel complexed with an NN2-type pincer ligand and a controlled release of CO gas from a solid precursor, works well with a range of benzylic bromides. Mechanistic studies suggest the intermediacy of carbon-centered radicals.

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis. It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacological therapy to date. Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy. In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clinical trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies. To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity. Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency. Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.